Home › Myelofibrosis › Texas › Dallas
Myelofibrosis clinical trials in Dallas, TX
5 studies for Myelofibrosis are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
RecruitingPhase 3
- Texas Oncology PA Dallas Presbyterian Hospital, Dallas
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
- Baylor University Medical Center, Dallas
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Dallas
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingPhase 3
- UT - SouthWestern, Dallas
Myelofibrosis trials in other cities
- Houston, TX19 studies
- New York City, NY18 studies
- Durham, NC12 studies
- Boston, MA12 studies
- Columbus, OH11 studies
- Seattle, WA11 studies
- Salt Lake City, UT10 studies
- Miami, FL10 studies
- Cleveland, OH9 studies
- Tampa, FL9 studies
- Atlanta, GA9 studies
- Nashville, TN9 studies
Other studies in Dallas
- Breast Cancer55 studies
- Non-Small Cell Lung Cancer52 studies
- Metastatic Cancer42 studies
- Heart Failure42 studies
- Cancer (all types)37 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity30 studies
- Ovarian Cancer28 studies
- Bladder Cancer27 studies
- Lung Cancer27 studies
- Endometrial Cancer24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.